

For the Board.

**Beatrice Ezerski,**

*Secretary to the Board.*

[FR Doc. 97-22131 Filed 8-20-97; 8:45 am]

BILLING CODE 7905-01-P-M

## RAILROAD RETIREMENT BOARD

### 20 CFR Part 367

RIN 3220-AB26

#### Collection of Debts

**AGENCY:** Railroad Retirement Board.

**ACTION:** Final rule.

**SUMMARY:** The Railroad Retirement Board (Board) amends its regulations pertaining to the collection of debts by offset against Federal payments to reflect amendments to section 3716 of Title 31 by the Debt Collection Improvement Act of 1996 (Pub. L. 104-134).

**DATES:** Effective Date: This Regulation will be effective August 21, 1997.

**ADDRESSES:** Secretary to the Board, Railroad Retirement Board, 844 North Rush Street, Chicago, Illinois 60611.

**FOR FURTHER INFORMATION CONTACT:** Michael C. Litt, General Attorney, Bureau of Law, Railroad Retirement Board, 844 North Rush Street, Chicago, Illinois 60611, (312) 751-4929, TDD (312) 751-4701.

**SUPPLEMENTARY INFORMATION:** Part 367 of the Board's regulations provides for the collection of debts by administrative offset under the authority of the Debt Collection Act of 1982, 31 U.S.C. 3716. The Debt Collection Improvement Act of 1996 (Pub. L. 104-134) amended 31 U.S.C. 3716 to provide for referral of delinquent Federal nontax debts to the Department of Treasury for administrative offset ("Treasury Offset Program"), and to provide for the mandatory referral of such debts over 180 days delinquent to the Treasury Offset Program, subject to certain exceptions. Accordingly, the Board amends this part to implement the provisions of Public Law 104-134.

Section 367.1 is revised to cite the authority of Public Law 104-134 and its provision for the referral of delinquent Federal nontax debts to the Treasury Offset Program.

Section 367.2 is amended to provide that only nontax debts will be referred to the Treasury Offset Program, and that a debt will not be referred if the Board's records show that foreclosure is pending on collateral securing the debt or if the debt has been referred to the Department of Justice or is otherwise in litigation with the Board.

Section 367.3 is amended to provide that the Board shall refer nontax debts over 10 days delinquent to the Treasury Offset Program and that in cases of mandatory referral of delinquent debt, unless otherwise directed by the Secretary of Treasury, the Board is not required to determine whether administrative offset is feasible, allowable, and appropriate.

The Board, with the concurrence of the Office of Management and Budget, has determined that this is not a significant regulatory action under Executive Order 12866. Therefore, no regulatory impact analysis is required. There are no new information collections associated with this rule.

The Board published this rule as an interim final rule on April 21, 1997 (62 FR 19219) and comments were invited by June 20, 1997. No Comments were received. Accordingly, the interim final rule is adopted as a final rule without change.

Dated: August 12, 1997.

By Authority of the Board.

For the Board.

**Beatrice Ezerski,**

*Secretary to the Board.*

[FR Doc. 97-22130 Filed 8-20-97; 8:45 am]

BILLING CODE 7905-01-P-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### 21 CFR Part 522

#### Implantation or Injectable Dosage Form New Animal Drugs; Doramectin

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Final rule.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a supplemental new animal drug application (NADA) filed by Pfizer, Inc. The supplemental NADA provides for use of doramectin in cattle to control infections and to protect from reinfection with *Cooperia punctata* and *Dictyocaulus viviparus* for 28 days after treatment. This supplemental NADA also amends the wording of the claim for protection against infection or reinfection with *Ostertagia ostertagi* for 21 days and incorporates the claim into the new indication statement.

**EFFECTIVE DATE:** August 21, 1997.

**FOR FURTHER INFORMATION CONTACT:** Thomas Letonja, Center for Veterinary Medicine (HFV-135), Food and Drug

Administration, 7500 Standish Pl., Rockville, MD 20855, 301-594-1643.

**SUPPLEMENTARY INFORMATION:** Pfizer, Inc., 235 East 42d St., New York, NY 10017-5755, is sponsor of NADA 141-061 that provides for the use of Dectomax® 1% injectable solution (doramectin) for treatment and control of certain gastrointestinal roundworms, lungworms, eyeworms, grubs, lice, and mange mites of cattle, and protection against infection or reinfection with *O. ostertagi* for up to 21 days. The firm filed a supplemental NADA that provides for added use in cattle to control infections and to protect from reinfection with *C. punctata* and *D. viviparus* for 28 days after treatment. The supplemental NADA also amends the wording of the claim for " \* \* \* protection against infection or reinfection with *Ostertagia ostertagi* for 21 days" and incorporates the claim into the new indication statement. The supplemental NADA is approved as of July 18, 1997, and the regulations are amended in 21 CFR 522.770(d)(2) to reflect the approval. The basis of approval is discussed in the freedom of information summary.

In accordance with the freedom of information provisions of 21 CFR part 20 and 514.11(e)(2)(ii), a summary of data and information submitted to support approval of this application may be seen in the Dockets Management Branch (HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857, from 9 a.m. to 4 p.m., Monday through Friday.

Under section 512(c)(2)(F)(iii) of the Federal Food, Drug, and Cosmetic Act, this supplemental approval for food-producing animals qualifies for 3 years of marketing exclusivity beginning July 18, 1997, because the supplement contains substantial evidence of the effectiveness of the drug involved, studies of animal safety or, in the case of food-producing animals, human food safety studies (other than bioequivalence or residue studies) required for approval of the supplement and conducted or sponsored by the applicant. Exclusivity applies only to the added indication to control infections and to protect cattle from reinfection with *C. punctata* and *D. viviparus* for 28 days after treatment.

The agency has determined under 21 CFR 25.24(d)(1)(i) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.